{
    "2018-06-12": [
        [
            {
                "time": "2018-01-03",
                "original_text": "Eli Lilly, AstraZeneca Shares Fall After Halting Alzheimer's Drug Test",
                "features": {
                    "keywords": [
                        "Lilly",
                        "AstraZeneca",
                        "Shares",
                        "Fall",
                        "Halting",
                        "Alzheimer's",
                        "Drug",
                        "Test"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-04",
                "original_text": "AstraZeneca, Lilly Join Others On Failed Alzheimer's Drug Heap",
                "features": {
                    "keywords": [
                        "AstraZeneca",
                        "Lilly",
                        "Failed",
                        "Alzheimer's",
                        "Drug"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-05",
                "original_text": "AstraZeneca, Lilly halt tests of experimental Alzheimer's treatment",
                "features": {
                    "keywords": [
                        "AstraZeneca",
                        "Lilly",
                        "halt",
                        "tests",
                        "experimental",
                        "Alzheimer's",
                        "treatment"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-06",
                "original_text": "Allergan's Second Anti-CGRP Drug Positive in Mid-Stage Study",
                "features": {
                    "keywords": [
                        "Allergan",
                        "Anti-CGRP",
                        "Drug",
                        "Positive",
                        "Mid-Stage",
                        "Study"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-01-07",
                "original_text": "Lilly & AstraZeneca Scrap Studies on Alzheimer's Candidate",
                "features": {
                    "keywords": [
                        "Lilly",
                        "AstraZeneca",
                        "Scrap",
                        "Studies",
                        "Alzheimer's",
                        "Candidate"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-08",
                "original_text": "Alzheimer's Research Stumbles Again: What's the Road Ahead?",
                "features": {
                    "keywords": [
                        "Alzheimer's",
                        "Research",
                        "Stumbles",
                        "Road",
                        "Ahead"
                    ],
                    "sentiment_score": -0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "research"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-09",
                "original_text": "Lilly-AstraZeneca latest to abandon Alzheimer's drug trials",
                "features": {
                    "keywords": [
                        "Lilly",
                        "AstraZeneca",
                        "abandon",
                        "Alzheimer's",
                        "drug",
                        "trials"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-10",
                "original_text": "Another Alzheimer's Drug Fails as Lilly, Astra Halt Tests",
                "features": {
                    "keywords": [
                        "Alzheimer's",
                        "Drug",
                        "Fails",
                        "Lilly",
                        "Astra",
                        "Halt",
                        "Tests"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-11",
                "original_text": "Update on Phase 3 Clinical Trials of Lanabecestat for Alzheimer's Disease",
                "features": {
                    "keywords": [
                        "Phase",
                        "3",
                        "Clinical",
                        "Trials",
                        "Lanabecestat",
                        "Alzheimer's",
                        "Disease"
                    ],
                    "sentiment_score": -0.3,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "clinical trials"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-12",
                "original_text": "[$$] AstraZeneca and Eli Lilly scrap Alzheimer’s drug trial",
                "features": {
                    "keywords": [
                        "AstraZeneca",
                        "Eli",
                        "Lilly",
                        "scrap",
                        "Alzheimer’s",
                        "drug",
                        "trial"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-13",
                "original_text": "AstraZeneca, Eli Lilly To Discontinue Lanabecestat Trials In Alzheimer's",
                "features": {
                    "keywords": [
                        "AstraZeneca",
                        "Eli",
                        "Lilly",
                        "Discontinue",
                        "Lanabecestat",
                        "Trials",
                        "Alzheimer's"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}